,72 Therefore, we combined alpelisib with sapanisertib, an mTORC1/2 inhibitor, which has shown more potent anticancer activity compared to first‐generation mTOR inhibitors and is currently in clinical trials for various indications, including glioblastoma, nonsmall cell lung, bladder and breast cancer (NCT02133183, NCT04250545, NCT03047213, NCT02465060).72 This evidence concerns the gene MTOR and breast carcinoma.